Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs ENT 01 (Primary)
- Indications Constipation; Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- Acronyms KARMET
- Sponsors Enterin
- 08 Nov 2022 Primary endpoint has been met, (the number of complete spontaneous bowel movements (CSBMs) per week.), as per Results published in the Annals of Internal Medicine
- 08 Nov 2022 Results published in the Annals of Internal Medicine
- 05 Jan 2021 Planned End Date changed from 1 May 2021 to 1 Sep 2021.